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Objective: Treatment options available to patients with rheumatoid arthritis (RA) are ever-changing, and
understanding the similarities and differences of efﬁcacy and safety between different RA therapies is of
key importance in order to facilitate treatment decisions by both the patient and physician. Very few
head-to-head, peer-reviewed trials exist; instead, evidence for efﬁcacy of treatments is often ascertained
from placebo-controlled trials, registries and meta-analyses, which often do not sufﬁciently address the
relative effectiveness of two medications.
Methods: A targeted review of indirect comparison methods, and ongoing and published clinical studies
assessing the efﬁcacy and safety, and the comparative efﬁcacy and safety of biologic disease modifying
antirheumatic drugs in RA.
Results: Critical elements that should be considered when designing head-to head trials are described
using examples of true head-to-head and placebo-controlled randomized controlled trials (RCTs). The
appropriate use of head-to-head trial designs is demonstrated by reviewing different examples of well-
designed clinical trials, and an overview is presented of the challenges associated with indirect
comparisons. This review also examines the use of studies comparing therapies to placebo, highlighting
the difﬁculties associated with the interpretation of these studies.
Conclusions: For comparative trials to contribute to evidence-based decision making in the treatment of
RA, patient populations and treatment regimens as similar as possible to those used in routine clinical
practice should be employed and the trial should be appropriately designed to answer the speciﬁc
question asked.
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The changing landscape in rheumatoid arthritis (RA) therapeu-
tic options underscores the need for informed treatment choices
by physicians and patients. To date, the vast majority of evidence
on the effectiveness of targeted therapies for the treatment of RA
has come from placebo-controlled trials, registries, and meta-
analyses, none of which adequately assess the relative effective-
ness of two medications in a homogenous population of patients.
The use of placebo as a control for longer than 3 months in RA
clinical trials is now perceived as unethical, as there are numerous
effective medications currently available and the goal of therapy is
to signiﬁcantly reduce clinical symptoms, improve function, and
limit disease progression [1]. With multiple therapeutic options
available, it is imperative to understand the comparability of
different targeted therapies for RA. However, there are few peer-r HS Journals, Inc. This is an open
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leischmann)reviewed, published, direct head-to-head trials; in their place,
indirect comparisons such as network meta-analysis have become
the benchmark (even in treatment recommendations), despite
their documented limitations and inconsistencies [2]. Conse-
quently, a number of gaps still remain in our understanding of
the relative efﬁcacy and safety proﬁles of all available therapies
[1,3]. Direct head-to-head trials comparing effective treatments in
RA allow for evidence-based treatment comparisons and, there-
fore, they can be of greater clinical relevance and importance than
placebo-controlled studies [3].
In this article, the study designs of currently ongoing and
completed head-to-head and comparison trials in RA are evaluated
to highlight the wealth of information they can provide, especially
when interpreted within their appropriate context. In addition, we
underscore the fact that both superiority and non-inferiority trials
have a signiﬁcant role to play, which is dependent on the questions
being addressed. For the purposes of this review, we use examples
from what we consider true head-to-head trials (e.g., AMPLE,
ADACTA, and EXXELERATE) and placebo-controlled randomizedaccess article under the CC BY-NC-ND license
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Standard and ATTEST) to highlight the critical elements that need
to be considered in designing a head-to-head trial, whether within
class or across modes of action. Depending on the question being
asked, the choice of comparator, endpoints, blinding, and trial
population would be different; here we address the main points
for consideration. We also discuss some aspects of the methodo-
logical limitations of indirect comparisons, such as meta-analyses
and how they can lead to false conclusions.Why are there so few head-to-head studies?
Direct head-to-head trials have the advantage of comparing
therapies in the same study at the same time, making the results
easier to interpret and understand [4]. However, there are rela-
tively few head-to-head comparisons of targeted therapies in RA
[5]. One reason suggested for the small number of head-to-head
trials is that there may be less incentive for industry to sponsor
this type of study. In the past, regulatory authorities did not
formally require head-to-head studies proving the efﬁcacy of a
new drug over an existing drug when ﬁling for a new treatment
[6]. Furthermore, such RCTs may not serve the commercial
interests of the industry sponsor, as they run the risk that their
drug is shown to be less effective than the competitor [1].
However, regulatory authorities are increasingly asking for head-
to-head trials and they are becoming increasingly important for
comparative effectiveness research and the work of governmental
research organizations [7,8].Challenges and pitfalls of indirect comparisons
In the absence of direct head-to-head evidence, a multitude of
indirect comparisons have been used to evaluate therapies in RA.
With indirect comparisons, different interventions are compared
using data from separate studies. For a standard meta-analysis
comparing two different interventions, the major assumption is
that results from different trials are sufﬁciently homogenous to
allow pooling of the data [4]. More complex methods such as
network meta-analysis are used to conduct adjusted indirect
comparisons of multiple interventions, with the assumption that
trials are sufﬁciently similar in terms of modiﬁers of relative
treatment effect such as patient characteristics, settings, and
outcomes [4].
There are several methodological limitations to the use of
indirect comparisons for comparative efﬁcacy research. Studies
included in indirect comparisons are highly unlikely to have
identical study designs. Therefore, confounding factors and sour-
ces of trial heterogeneity must be taken into account [9]. For
example, subtle differences in patient populations between trials
can arise with trends in time. Exclusion criteria may differ
between clinical trials, particularly with regard to safety aspects;
patients with certain comorbidities (e.g., tuberculosis infection)
will be identiﬁed, and thus excluded from subsequent trials [9].
Differences in study setting also have an impact, as certain
comorbidities may be more prevalent in particular regions [9].
Comparing trials without addressing contextual details such as
these may generate inaccurate results, and thus misleading con-
clusions [9]. In a survey of systematic reviews, a range of
methodological problems were identiﬁed in the application of
indirect comparisons, which in some cases may invalidate their
results [4].
Many published network meta-analyses for targeted therapies
in RA have come to different conclusions regarding their relative
efﬁcacy [10]. Multiple factors may explain these inconsistencies,such as the speciﬁc RCTs included, analysis of heterogeneity and
the efﬁcacy outcomes assessed [10]. These weaknesses limit the
usefulness of indirect comparisons as part of formal decision-
making strategies in RA [10].
Data from patient registries are also widely used to indirectly
compare the efﬁcacy and safety of different therapeutics. As
patients are not randomized to a treatment group, the outcomes
can be strongly affected by confounding by indication, which may
inﬂate or reduce the magnitude of a particular association [11]. In
theory, these issues can be partly overcome with very large patient
registries that include all patients on all therapies, a detailed
explanation of why patients were selected for certain treatments,
detailed reasoning for why patients changed therapies, and exten-
sive clinical information covering all efﬁcacy parameters. In the
absence of this information, statistical methods, including cova-
riate adjustments, covariate matching, and propensity scoring, can
be used to mitigate the effects of any confounding factors and
reduce bias [12]. However, each technique has its own speciﬁc
limitations; covariate adjustments can lead to overﬁtting [13],
matching requires very large registries to achieve groups with
sufﬁcient patient numbers [14], and propensity scoring can only be
used if the patient could receive either treatment being compared
as it assumes that there is an equal probability of the patient
receiving either treatment. Furthermore, propensity scoring does
not include unobserved covariates, so residual confounding may
still take place [15].Choice of superiority or non-inferiority study design
Depending on the trial hypothesis, head-to-head studies may
be designed as a superiority, equivalence or non-inferiority trial.
The aim of a superiority trial design is to demonstrate that one
intervention is superior to another, with a sample size based on a
pre-speciﬁed minimum clinically important difference. Equiva-
lence trials test whether the effects of two interventions are the
same within pre-speciﬁed equivalence margins. True equivalence
trials require very large numbers of patients, and are rarely used.
Non-inferiority trials are designed to determine whether the effect
of one intervention is no worse than an active control intervention
by more than a pre-speciﬁed non-inferiority margin. Non-
inferiority trials are used more often than equivalence trials, as
they better ﬁt the research question of interest and require fewer
patients [10].
The majority of industry sponsored head-to-head trials have a
non-inferiority design [16], with the aim of demonstrating non-
inferior efﬁcacy compared to an active control. Non-inferiority
trials require a pre-speciﬁed, narrow margin of non-inferiority
which quantiﬁes a level where the new therapy is considered non-
inferior to the standard therapy. Several factors must be consid-
ered when deciding an appropriate non-inferiority margin, such as
the deﬁnition of a clinically acceptable difference, which can be
subjective. As sample size is exponentially correlated with the
non-inferiority margin, non-inferiority trials often require large
sample sizes, which is a recognized limitation of the design. If too
few patients are enrolled, and the study is underpowered, the
conclusion of non-inferiority cannot be drawn [6]. Investigators
may accept wide non-inferiority margins upfront (or worse,
during the trial) in order to constrain high sample sizes which
can lead to an incorrect conclusion of non-inferiority. Careful
consideration should also to be given to the analyzed patient
population. The intention-to-treat (ITT) population includes
all patients randomized, whereas the per-protocol (PP) population
excludes all patients with major protocol violations [17].
Consequently, the ITT population tends to bias the results toward
non-inferiority, whereas the PP population may potentially bias
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For non-inferiority trials, it is recommended to analyze trial
data using both the PP and ITT populations. For superiority
trials, because of the tendency towards equivalence, the
ITT population is more conservative and therefore most
appropriate [17].
The choice of either a superiority or a non-inferiority design in
a head-to-head study depends on the intentions of the investi-
gator. The sponsor or investigator designing the trial has to decide
prior to the start of the trial what they wish to demonstrate,
balancing any potential beneﬁts with the risks of this decision.
Most commercial sponsors who want to demonstrate comparative
effectiveness of their drug will use a non-inferiority design. The
study sponsor may consider performing a superiority comparison
on the ITT population using the data from the non-inferiority trial,
but only after non-inferiority has formally been proven [18]. When
using this approach appropriate statistical adjustments are
required to prevent inﬂation of Type I error (i.e., hierarchical
testing or the Hochberg method).
If the study sponsor believes that their already licensed drug is
more effective than its comparator and should be prioritized (i.e.,
in treatment recommendations), particularly when most clinicians
believe that both drugs are equally effective, the sponsor may
decide to perform a superiority head-to-head trial; for example,
ADACTA [19] or EXXELERATE (NCT01500278) in RA, despite
insufﬁcient literature evidence for superiority. If the trial does
not show superiority, they still have a licensed drug; but if
superiority is proven, they will have gained a commercial advant-
age. By contrast, if the designer is a clinician who wants to know
whether Drug A or Drug B should be prioritized for the treatment
of RA, in the case where most clinicians think that both are equally
effective, a well-designed non-inferiority trial, such as AMPLE [3],
may be more informative than a superiority trial that misses its
endpoint.
In addition to demonstrating greater effectiveness, a well-
designed superiority trial has the potential to address a number
of the questions included in the 2013 update of the EULAR
management recommendations for RA and the recently published
ACR guidelines for the management of RA, such as how compara-
ble different targeted agents are (including those within the same
class) [20,21]. Within the RA ﬁeld, EXXELERATE is currently the
only ongoing head-to-head, within class, superiority trial, and so
may be able to provide these answers.
In the EXXELERATE study, patients were assigned 1:1 to either
certolizumab pegol or adalimumab, both in combination with
MTX; if patients did not respond by Week 12 [i.e., achieve low
disease activity (LDA; DAS28(ESR) r 3.2) or DAS28(ESR) reduction
from baseline of Z 1.2] they were switched to the other anti-TNF.
Current treat-to-target guidelines state that drug therapy should
be adjusted if patients do not achieve their treatment target within
3–6 months from starting therapy [22]; EXXELERATE has the
potential to validate the use of the week 12 decision point. In
addition, EXXELERATE is the ﬁrst study that will assess the safety
of an immediate switch between anti-TNFs, with no washout
period. Immediate switching occurs in daily clinical practice and
is in line with current recommendations, but the safety of this
practice has not been evaluated in a head-to-head clinical trial
to date.
Regardless of their choices, investigators must understand the
strengths and limitations of their study design and interpret the
results appropriately. The main outcomes of superiority trials are
often interpreted as if they were conducted as non-inferiority
trials, which can lead to misconceptions regarding the results [6].
For example, in an RCT evaluating the superiority of Drug A over
Drug B that does not meet its endpoint, the only conclusion which
can be drawn is that there was no evidence that Drug A is betterthan Drug B. It is not correct to interpret these results as showing
that Drug A is equivalent or non-inferior to Drug B.Studies comparing targeted therapies to placebo
The inclusion of more than one targeted therapy in a study does
not necessarily make it a true head-to-head comparison. Some
studies of targeted therapies in RA include an active control arm to
determine “relative efﬁcacy,” yet carefully avoid any formal com-
parison of the targeted therapies. Such studies are not true head-
to-head trials, as they are designed with the statistical power for
comparing targeted therapies against a common placebo group
only, not against each other. Examples of this include the ORAL-
Standard study, which compared tofacitinib with placebo in the
context of adalimumab [23], and the ATTEST study [24], which
evaluated inﬂiximab and abatacept compared to placebo. In the
primary publication of the ATTEST study, the authors focused on
the safety results of the trial, avoiding any formal comparison
between abatacept and inﬂiximab [24]. Only post hoc, when the
positive trial results were conﬁrmed, were abatacept and inﬂix-
imab described as having “similar efﬁcacy,” but without scientiﬁc
proof due to the lack of formal comparison [24]. Study designs of
this type are summarized in Table 1. They invite misinterpretation
of results and should be reviewed with caution.
A recent exception is RA-BEAM (NCT01710358) [25], a trial
comparing baricitinib and adalimumab to placebo, which was able
to demonstrate superiority of baricitinib over adalimumab as a
secondary endpoint.Design features of head-to-head studies in RA
True head-to-head studies are appropriately designed and
powered to allow formal comparison of different therapies, and
are of greater clinical relevance than studies which do not allow
comparative efﬁcacy conclusions to be drawn. Completed and
ongoing head-to-head studies of targeted therapies in RA are
summarized in Table 2.
Use of blinding
When designing head-to-head studies, investigators should
consider the implications of non-blinding, single-blinding, or
double-blinding. Blinding in a head-to-head study with active
comparators is complex if the therapies have different modes of
administration or are obviously visually different. The goal of
blinding in clinical trials is to avoid expectation bias inﬂuencing
treatment effect [30]. Depending on the context, it may be less
important to ensure optimal blinding. Head-to-head trials are
often conducted to determine effectiveness rather than efﬁcacy.
As the efﬁcacy of the drug has formally been proven, and the drug
licensed, the aim is to investigate whether licensed Drug A has
advantages over licensed Drug B when applied in clinical care, i.e.,
without blinding but with prognostic similarity (randomization).
In general, however, patients’ and study personnel’s belief that a
drug is non-inferior may bias a result towards non-inferiority [18].
The authors of the AMPLE non-inferiority study of subcuta-
neous abatacept vs. subcutaneous adalimumab in RA, acknowl-
edged that the single-blinded nature of the study could be
considered a limitation [3]. Adalimumab has unique visual char-
acteristics, which prevented proper masking of the comparator
agent, and thus this was not a double-blind study; investigators,
coordinators, and joint assessors were blinded but patients were
not [3]. Due to technical issues, the adalimumab syringes could not
be manufactured with dummy adalimumab. The investigators felt
Table 1
Comparison of studies in RA comparing targeted therapies in the context of placebo
Study Comparison Primary end point Population Blinding Mono or þMTX
NCT00279760 Phase I/II (results
pending)
ABA vs. PBO; belatacept
vs. PBO
Relative safety and
preliminary efﬁcacy
Previously failed Z1
DMARD
Double (both IV) Not clear
Superiority
Genovese et al. Phase Iib [26] OKZ Week 12 DAS28(CRP) CFB Must have failed at least
one prior anti-TNF
Double (IV vs. SC) þMTX (stable
dose)Superiority vs. PBO, in context
of TCZ
Fleischmann et al. Phase Iib [27] TOF vs. PBO; ADA vs. PBO Week 12 ACR20 ADA naïve; previously
failed Z1 DMARD
Double (PO vs. SC) Mono
Superiority
ALTARA Phase II [28] PTZ Week 12 DAS28(ESR) Active RA, inadequate
response to DMARDs
Double (both SC) þoral DMARDs
Superiority vs PBO, in context
of ADA
ORAL-Standard Phase III [23] TOF Month 6 ACR20 ADA-naïve (if previously
treated, must have
responded to anti-TNF)
Double (PO vs. SC) þMTX
Superiority vs. PBO, in context
of ADA
Month 3 HAQ-DI CFB
Month 6 DAS28-4 (ESR)
REM (o2.6)
ATTEST Phase III [24] ABA safety Month 6 DAS28(ESR) CFB Naïve to ABA and anti-TNF Double (both IV) þMTX
Superiority vs. PBO, in context
of IFX
ABA, abatacept; ADA, adalimumab; CFB, change from baseline; IFX, inﬂiximab; IV, intravenous; OKZ, olokizumab; PBO, placebo; PO, oral; PTZ, pateclizumab; SC,
subcutaneous; TCZ, tocilizumab; TOF, tofacitinib.
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placebo group and both therapies were known to be effective,
nevertheless, the patients were aware of which therapy they were
taking. As AMPLE compared two already licensed drugs, double-
blinding was not truly necessary to demonstrate that subcuta-
neous abatacept is non-inferior to subcutaneous adalimumab, as
the trial is about effectiveness rather than about efﬁcacy.
However, if the context is different, and a regulatory agency
requests an “active control arm” (standard of care) in a Phase III
trial (i.e., a head-to-head trial) then blinding is mandatory,
regardless of whether it is a superiority or a non-inferiority design.
One approach for blinding treatments that differ in appearance is
the double-dummy blinding strategy. With this approach, the
comparators do not need to look identical, as a placebo is given
to match the appearance of each study drug [31]. However, this
can be technically difﬁcult, requiring additional research expense
and time to produce the two placebos. The double-dummy design
also has the disadvantage of requiring patients to take two study
medications, which may increase the risk of non-compliance [31].Choice of comparators
The choice of comparator needs to be considered carefully in a
head-to-head study design; the appropriateness of comparing to
either active therapy plus MTX or monotherapy needs to be
considered, as does the use of conventional synthetic (cs)DMARDs
other than MTX. However, there is not necessarily a “good” or
“bad” choice when it comes to comparators, unlike when choosing
between a study design; the choice of comparator depends on
what the investigator or study sponsor would like to know. The
key is that the studies must be interpreted correctly according to
their design.
For example, if a sponsor is designing a Phase III trial with the
aim of gaining approval for a new drug, a placebo-controlled RCT
with early escape after 16 weeks would be appropriate. By
contrast, an active comparator might be more appropriate to
investigate elements of effectiveness of a particular new treat-
ment. Anti-TNFs in combination with MTX are generally consid-
ered the best active comparators as they have the tightest
conﬁdence intervals for efﬁcacy and longest safety record of the
targeted treatments [1], with the exception of MTX treatmentintolerance. This again depends on what the investigator wishes to
demonstrate.
The ADACTA study was designed to evaluate the superior
efﬁcacy and safety of tocilizumab vs. adalimumab as monotherapy
in patients with RA who had failed or were intolerant to MTX, or
where continued treatment with MTX was considered inappro-
priate [19]. However, as it has been demonstrated that adalimu-
mab plus MTX is superior to adalimumab monotherapy [32], the
study design limits the interpretation of the ADACTA study. The
study design can only demonstrate superiority of tocilizumab over
adalimumab in a situation where MTX cannot be used, but it
cannot be established whether tocilizumab plus MTX or tocilizu-
mab monotherapy is superior to adalimumab plus MTX.
The use of anti-TNF monotherapy as the comparator raises
study design issues in general. Previous analyses have indicated
adalimumab monotherapy is less effective than the combination
with MTX [32]. This has also been shown with etanercept [33] and
golimumab [34]. Therefore, studies using anti-TNF monotherapy as
a comparator (e.g., ADACTA and SARIL-RA MONARCH) may not be
justiﬁed, other than in a select group of patients.
Theoretically, a third arm with a placebo comparator in head-
to-head trials is beneﬁcial. For example, in a head-to-head trial
comparing two active comparators, a placebo arm will provide
reference and prove that both therapies are more effective than
placebo (“assay-sensitivity”). Unfortunately, the costs associated
with introducing a third arm in a clinical trial usually make this
approach unfeasible.
Choice of endpoint
In the European Medicines Agency (EMA) draft guidelines, ACR
response criteria, DAS, DAS28(ESR), SDAI, and CDAI are all consid-
ered acceptable for use as primary or secondary endpoints in RA
clinical trials [35]. The ACR20 is an excellent indicator of whether a
medication is effective while the DAS, DAS28(ESR), CDAI, and SDAI
are better indicators for assessing the true magnitude of response,
especially where acute phase reactants are involved. The majority
of head-to-head RA studies use ACR20 or DAS28(ESR) as the
primary endpoint (Table 2) although more trials are incorporating
the SDAI and CDAI.
Assessment of structural damage in head-to-head studies is
also important. Endpoints such as CDAI, SDAI, and DAS28
Table 2
Comparison of completed and ongoing head-to-head studies of targeted therapies in RA
Study Comparison Primary end point Population Blinding Mono or þMTX
Completed studies
EXXELERATE (NCT01500278) Phase IV CZP vs. ADA Week 12 ACR20 response Biologic and JAK inhibitor-
naïve
Single (both SC) þMTX
Superiority Week 104 DAS28(ESR) r3.2
RA-BEAM (NCT01710358) Phase III Study Comparative efﬁcacy baricitinib
and ADA vs. PBO
Week 12 ACR20 response Biologic-naïve Double (PO vs. SC) þMTX
Superiority
EARTH Explorer 2 (NCT01715896)
Phase II Study
Mavrilimumab vs. GOL Week 24 ACR20/50/70, DAS28
o2.6 and HAQ-DI improvement 40.25
Biologic-naïve other than anti-
TNFs.
Double (both SC) þMTX
Superiority Inadequate response to r2
anti-TNFs
other than GOL
NCT01373151 Phase Iib (Results pending) BMS-945429 vs. ADA Week 12 ACR20 response rate Biologic-naïve Double (both SC) 7MTX
Superiority
SARIL-RA ASCERTAIN (NCT01768572)
Phase III (results pending)
SAR vs. TCZ Safety at week 24 Previously failed anti-TNF
treatment
Double (SC vs. IV) þDMARDs
Not clear
AMPLE Phase IIIb [29] ABA vs. ADA ACR20 at 1 year Biologic-naïve Single (both SC) þMTX
Non-inferiority
ADACTA Phase IV [19] TCZ vs. ADA Week 24 DAS28(ESR) CFB Biologic-naïve Double (SC vs IV) Mono
Superiority
ORBIT (NCT01021735) Phase IV Study RTX vs. ETN/ADA Month 12 DAS28(ESR) CFB Biologic-naïve Open-label (SC vs. IV) Not speciﬁed
Superiority
Ongoing studies
NCT02287922 Phase II Study ALX-0061 vs TCZ Week 12 ACR20 response Naïve to anti IL-6s. Must not
have received any biologic/
tsDMARD o6 months prior
to screening
Double-blind ALX-
0061;
Open-label TCZ arm
(both SC)
Mono. with ALX-0061; Not
speciﬁed for TCZNot clear
SARIL-RA-MONARCH (NCT02332590)
Phase III Study
SAR vs. ADA Week 24 DAS28(ESR) CFB Biologic and JAK inhibitor-
naïve
Double-blind (both SC) Mono
Superiority
SIRROUND-H (NCT02019472) Phase III Sirukumab vs. ADA Week 24 DAS28(ESR) CFB Biologic and JAK inhibitor-
naïve
Double (both SC) Mono
Superiority Week 24 ACR50 response
SWITCH Study (NCT01295151) Phase
IV Study
Anti-TNFs (ETN/ADA/CZP/IFX/GOL)
vs. ABA vs. RTX
Change in disease activity (DAS28)
at 6 months
All patients had been treated
with
an anti-TNF
Open-label [All SC
except for
RTX and IFX (IV)]
þMTX
Not clear
NCT01331837 Phase IV Study TCZ vs. ETN Time from randomization to a
major cardiac event
TCZ and ETN naïve. Inadequate
response
to Z1 non-biologic DMARD
Open-label (IV vs. SC) Not speciﬁed
Superiority
ORAL STRATEGY (NCT02187055)
Phase IV Study
TOF vs. ADA 6 month ACR50 response Naïve to ADA and TOF Double (both SC) 7MTX
Superiority
NORD-STAR (P1: NCT01491815) (P2:
NCT02466581) Phase IV Study
Active conventional therapy
vs. CZP/ABA/TCZ
Period 1
CDAI remission at Week 24,
radiographic progression at Week 48
Naïve to DMARDs for
rheumatic diseases
Open-label, blinded-
assessor
(CZP and ABA: SC;
TCZ: IV)
þMTX
Not clear Period 2
proportion maintaining
LDA (CDAI) 24 weeks after dose
reduction
NCT02092467 Phase IV Study TOF vs. ADA/ETN Malignancies (excluding non-
melanoma skin cancer) and incidence of
MACE at 5 years
Not stated Open-label (PO vs. SC) Not speciﬁed
Not clear
ABA: abatacept; ADA: adalimumab; CFB: change from baseline; CZP: certolizumab pegol; ETN: etanercept; GOL: golimumab; IFX: inﬂiximab; IV: intravenous; OKZ: olokizumab; PBO: placebo; PO: oral; PTZ: pateclizumab; RTX:
rituximab; SAR: sarilumab; SC: subcutaneous; TCZ: tocilizumab; TOF: tofacitinib.
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of residual inﬂammation, but cannot assess structural progression;
however, the EMA draft guidelines recommend that structural
damage be routinely monitored by X-rays in pivotal long-term
trials [35]. The AMPLE head-to-head study of abatacept vs.
adalimumab assessed long-term radiographic outcomes as well
as efﬁcacy [29]. Functional assessment is also a major endpoint,
usually by evaluating the change in HAQ-DI.
In the ADACTA study, which compared tocilizumab to adali-
mumab, the primary endpoint used was change in DAS28(CRP)
from baseline at week 24 [19]. DAS28 response is heavily inﬂu-
enced by acute phase reactants. As tocilizumab is an anti-IL-6
receptor antibody, and IL-6 is a strong promoter of acute phase
reactants, choosing DAS28 as the primary endpoint introduces a
bias favoring tocilizumab, because IL-6 inhibition may strongly
impact the DAS28 value, with signiﬁcant reduction solely due to
effects on IL-6. The FUNCTION trial [36], which compared tocili-
zumab with MTX using DAS28(ESR), has the potential to favor
tocilizumab over MTX due to the indirect inﬂuence of acute phase
reactants on ESR. For measures such as DAS28, where acute phase
reactants have high weight, effects on acute phase reactant values
might lead to differing remission rates with tocilizumab compared
with other drugs, even with no difference in clinical efﬁcacy
[37,38]. The use of the DAS(CRP) o2.6 as a threshold for remission
in the ADACTA study has also been questioned as more stringent
deﬁnitions of remission have been endorsed; there is no validation
of DAS(CRP) o2.6 deﬁning remission [39]. However, it should be
noted that for ADACTA (but not for FUNCTION), similar efﬁcacy
results were observed for change in CDAI, a secondary endpoint
which does not include an acute phase reactant.
Endpoint timing is also an important factor to consider in head-
to-head studies, as different comparators may be more effective at
different time points. For example, in the etanercept early RA
study of etanercept monotherapy vs. MTX, the ACR-N may have
favored etanercept earlier on in the study due to its speed of effect,
but at 1 year, when MTX would be maximally effective, the ACR20/
50/70 of etanercept monotherapy was identical to MTX mono-
therapy [40].
Study populations
One of the drawbacks of using head-to-head clinical trials to
evaluate comparative efﬁcacy is that these studies generally use
exclusion criteria similar to Phase II/III trials, which may not be
relevant to the general RA population [41]. For example, in the
ADACTA study, the investigators acknowledged that enrolling
patients with high disease activity [DAS28(ESR) 45.1] means that
the results from the study may not be generalizable to typical
clinical practice, where patients often receive targeted therapy
when they have moderate or low disease activity [19].
Dosing and escape arms
Head-to-head studies often serve as a judgement about effec-
tiveness, not efﬁcacy. This implies that dosing in head-to-head
studies should be in accordance with what is regularly prescribed
in clinical practice. In the ongoing SIRROUND-H study of siruku-
mab vs. adalimumab, patients in the adalimumab arm can escape
from receiving adalimumab every other week (Q2W) to every
week (QW), though studies have not shown a signiﬁcant improve-
ment in response in patients switching from adalimumab Q2W–
QW [32]. In clinical practice, patients are treated according to
treat-to-target guidelines [22]; if a clinical response is not
observed to one anti-TNF, the patient will be switched to another.
Patients who fail to respond following the switch are then
classiﬁed as anti-TNF non-responders. Predicting the populationof patients that are likely to be non-responders would have
important treatment implications. By switching non-responding
patients to drugs within the same class, EXXELERATE has the
potential to discriminate some of the deﬁning baseline character-
istics of this patient sub-population.
With rescue study designs it is important to understand the
primary endpoint. A patient who escapes should not be included
in efﬁcacy outcomes, as the escape may improve clinical outcomes
and increase efﬁcacy measures. Consequently, including the
patient in the original therapy group could give a false positive
result, despite rescue status. Rescue is likely only relevant in the
context of a pure efﬁcacy trial that should maintain blinding until
the primary endpoint has been reached.Conclusions
Head-to-head trials in RA are of increasing importance, as the
majority of studies are now focused on placing a treatment in the
appropriate treatment strategy. To date, there are a limited
number of ongoing superiority head-to-head trials in RA that have
been correctly designed to directly compare the efﬁcacy of
targeted therapies and so can draw conclusions as to whether
one treatment is more effective than another. When designing
head-to-head trials, investigators must consider carefully what the
aim of the trial is, and design the study appropriately. For
comparative trials to contribute to evidence-based decisions in
RA, they should use patient populations and treatment regimens
similar to those used in routine clinical practice [3]. Results from
head-to-head trials should always be correctly interpreted in their
appropriate context, taking into account the available evidence
and the study design.Acknowledgments
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